BrightEdge was founded by the American Cancer Society to invest in for-profit companies developing novel cancer therapeutics and diagnostics.
Palmetto GBA issued final local coverage determination for the tissue-based, 31-gene expression test, which determines a patient’s risk for metastatic disease.
The approvals allow the company to offer its PCR-based expression profile cancer risk tests in the state.
The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.
Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.
The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.
The company's new $14 million facility refinances its original $6 million loan, and adds capital for new growth.
The first tranche of the targeted $20 million financing round will be used to accelerate adoption of the company's melanoma test.
The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.
In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.